Citadel Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-8,300
| Closed | -$319K | – | 15545 |
|
|
2023
Q2 | $319K | Buy |
8,300
+2,100
| +34% | +$53.9K | ﹤0.01% | 8913 |
|
|
2023
Q1 | $144K | Buy |
6,200
+4,100
| +195% | +$97.7K | ﹤0.01% | 10713 |
|
|
2022
Q4 | $55K | Sell |
2,100
-13,500
| -87% | -$299K | ﹤0.01% | 12007 |
|
|
2022
Q3 | $307K | Buy |
+15,600
| New | +$313K | ﹤0.01% | 9530 |
|
|
2021
Q3 | – | Sell |
-45,800
| Closed | -$647K | – | 14960 |
|
|
2021
Q2 | $647K | Sell |
45,800
-1,200
| -3% | -$19.2K | ﹤0.01% | 9430 |
|
|
2021
Q1 | $730K | Buy |
47,000
+300
| +0.6% | +$4.89K | ﹤0.01% | 8849 |
|
|
2020
Q4 | $741K | Buy |
46,700
+44,700
| +2,235% | +$674K | ﹤0.01% | 7409 |
|
|
2020
Q3 | $24K | Buy |
+2,000
| New | +$26.8K | ﹤0.01% | 9825 |
|
|
2018
Q2 | – | Sell |
-2,200
| Closed | -$102K | – | 9428 |
|
|
2018
Q1 | $102K | Buy |
+2,200
| New | +$80.5K | ﹤0.01% | 7703 |
|
|
2015
Q3 | – | Sell |
-60
| Closed | -$9K | – | 9332 |
|
|
2015
Q2 | $9K | Buy |
+60
| New | +$9.91K | ﹤0.01% | 8447 |
|
Citadel Advisors's KDNY Position: Q3 2023 in Review
Citadel Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 86,464 shares — an estimated $3.32M sold.
Citadel Advisors first reported a position in KDNY in Q2 2015 and held it in 24 quarters. The position peaked at $13.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Citadel Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 86,464 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.32M.
- Citadel Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $13.4M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.